Glutathione‐enhancing agents protect against steatohepatitis in a dietary model
Open Access
- 23 February 2006
- journal article
- research article
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 20 (1) , 39-47
- https://doi.org/10.1002/jbt.20109
Abstract
Nonalcoholic fatty liver (NAFL) and steatohepatitis (NASH) may accompany obesity, diabetes, parenteral nutrition, jejeuno‐ileal bypass, and chronic inflammatory bowel disease. Currently there is no FDA approved and effective therapy available. We investigated the potential efficacy of those agents that stimulate glutathione (GSH) biosynthesis on the development of experimental steatohepatitis. Rats fed (ad libitum) amino acid based methionine‐choline deficient (MCD) diet were further gavaged with (1) vehicle (MCD), (2)S‐adenosylmethionine (SAMe), or (3) 2(RS)‐n‐propylthiazolidine‐4(R)‐carboxylic acid (PTCA). Results: MCD diet significantly reduced hematocrit, and this abnormality improved in the treated groups (p< 0.01). Serum transaminases were considerably elevated (AST: 5.8‐fold; ALT: 3.22‐fold) in MCD rats. However, administration of GSH‐enhancing agents significantly suppressed these abnormal enzyme activities. MCD rats developed severe liver pathology manifested by fatty degeneration, inflammation, and necrosis, which significantly improved with therapy. Blood levels of GSH were significantly depleted in MCD rats but normalized in the treated groups. Finally, RT‐PCR measurements showed a significant upregulation of genes involved in tissue remodeling and fibrosis (matrix metalloproteinases, collagen‐α1), suppressor of cytokines signaling1, and the inflammatory cytokines (IL‐1β, IL‐6, TNF‐α, and TGF‐β) in the livers of rats fed MCD. GSH‐enhancing therapies significantly attenuated the expression of deleterious proinflammatory and fibrogenic genes in this dietary model. This is the first report that oral administration of SAMe and PTCA provide protection against liver injury in this model and suggests therapeutic applications of these compounds in NASH patients. © 2006 Wiley Periodicals, Inc. J Biochem Mol Toxicol 20:39–47, 2006; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/jbt.20109Keywords
This publication has 34 references indexed in Scilit:
- Non-alcoholic steatohepatitis: review of a growing medical problemEuropean Journal of Internal Medicine, 2004
- Oxidative stress, KLF6 and transforming growth factor-β up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in ratsJournal of Hepatology, 2003
- Nonalcoholic Fatty Liver Disease: Pathogenesis and the Role of AntioxidantsNutrition Reviews, 2002
- Matrix metalloproteinases: a tail of a frog that became a princeNature Reviews Molecular Cell Biology, 2002
- Synergistic upregulation of metalloproteinase‐9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF‐κBFEBS Letters, 1998
- Matrix metal loproteinases and the development of cancerChemistry & Biology, 1996
- Reversible hepatic steatosis in patients treated with interferon alfa-2A and 5-fluorouracilCancer, 1995
- Polymyxin B Reduces Total Parenteral Nutrition‐Associated Hepatic Steatosis by Its Antibacterial Activity and by Blocking Deleterious Effects of LipopolysaccharideJournal of Parenteral and Enteral Nutrition, 1992
- Metabolic aspects of peroxisomal β-oxidationBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1991
- 2-Substituted thiazolidine-4(R)-carboxylic acids as prodrugs of L-cysteine. Protection of mice against acetaminophen hepatotoxicityJournal of Medicinal Chemistry, 1984